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Abstract
Background: Apolipoprotein M (apoM) was the carrier of the biologically active lipid mediator sphingosine-1-
phospate in high density lipoprotein cholesterol (HDL-C) and played a critical role in formation and maturation
of prebeta-HDL-C particles. The plasma apoM levels were decreased obviously in patients with type 2 diabetes
mellitus (T2DM). A new single-nucleotide polymorphism (SNP) C-724del in apoM promoter was associated with
a higher risk for coronary artery diseases (CAD) and myocardial infarction, could reduce promoter activities and
apoM expression in vitro. The primary aim of the present case-controls study was to investigate the effect of
apoM SNP C-724del on apoM expression in vivo and its association with T2DM susceptibility in an eastern Han
Chinese cohort.
Methods: Two hundred and fifty-nine T2DM patients and seventy-six healthy controls were included in this
study. Amplifying DNA of apoM proximal promoter region including SNP C-724del by Real-Time Polymerase
Chain Reaction (RT-PCR) and amplicons sequencing. The plasma apoM concentrations were assayed by enzyme
linked immunosorbentassay (ELISA).
Results: Four polymorphic sites, rs805297 (C-1065A), rs9404941 (T-855C), rs805296 (T-778C), C-724del were confirmed.
rs805297 (C-1065A) and rs9404941 (T-855C) showed no statistical difference in allele frequencies and genotype
distributions between T2DM patients and healthy controls just as previous studies. It’s worth noting that the difference
of rs805296 (T-778C) between these two groups was not found in this study. In SNP C-724del, the frequency of del
allele and mutant genotypes (del/del, C/del) were higher in T2DM patients compared with healthy controls
(p = 0.035; P = 0.040, respectively), while the plasma apoM levels of C-724del mutant allele carriers compared
with the wide-type homozygotes carriers were not statistically different in T2DM patients (18.20 ± 8.53 ng/uL
vs 20.44 ± 10.21 ng/uL, P = 0.245).
Conclusion: The polymorphism C-724del in the promoter region of the apoM gene could confer the risk
of T2DM among eastern Han Chinese. Unfortunately, the lowing of plasma apoM levels of C-724del mutant
allele carriers compared with the wide-type homozygotes carriers in T2DM patients was not statistically
different in present study, so further researchs were needed by enlarging the sample.
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Background
ApoM gene coded for a 26 kDa protein and located on
chromosome 6q21–q23 which was a high susceptibility
region to T2DM in genome-wide linkage analyses [1–3].
It was mainly present in high density lipoprotein choles-
terol (HDL-C) and lesser extent in low density lipopro-
tein cholesterol (LDL-C), very low density lipoprotein
cholesterol (VLDL-C), and chylomicrons [1, 4]. ApoM
was the carrier of the biologically active lipid mediator
sphingosine-1-phospate in HDL-C, played a critical role
in formation and maturation of prebeta-HDL-C particles
which could promote intracellular cholesterol efflux [5–7].
Several studies have identified promoter variants of apoM
were associated with CAD and T2DM. Xu et al. have
reported that the allele C carries of apoM rs9404941
(T-855C) polymorphism have an increased risk for CAD
in Chinese populations [8]. Wu et al. and Zhou et al.
have found that apoM rs805296 (T-778C) polymorph-
ism was significantly associated with type 1 diabetes
mellitus (T1DM) and T2DM in northern chinese popu-
lation [9, 10]. Studies on 17 SNPs of apoM showed that
apoM SNPs rs805297 (C-1065A) was associated with
T2DM duration and SNPs rs707922 (G-1837T) TT
genotype significantly increased the total cholesterol
(TC) and LDL levels in patients with T2DM [11]. How-
ever, the genetic marker was distinct in different area
such as northern and southern of China [12, 13], so the
relationship between apoM rs805296 (T-778C) and the
susceptibility of T2DM was not found in the southern
Chinese population [11]. A new SNP C-724del, in the
proximal promoter of apoM, was significantly associ-
ated with a higher risk for CAD and myocardial infarc-
tion, obviously decreased promoter activities and apoM
expression in vitro [14, 15]. The primary aim of the
present case-controls study was to investigate the effect
of SNP C-724del on apoM expressions and its association




Two hundred and fifty-nine patients (149 males and 110
females) who were diagnosed T2DM by the WHO
criteria [fasting glucose ≥7.0 mmol/L (126 mg/dL) or
2-h glucose ≥11.1 mmol/L (200 mg/dL)] [16]. Exclusion
criteria were hematologic neoplastic, hepatic, thyroid, car-
diac, autoimmune diseases or non diabetic kidney disease.
Seventy-six age- and gender-matched healthy people (40
males and 36 females) who were good general health, no
significant past medical history, and documented normal
fasting blood glucose and glucose intolerance were se-
lected as the controls group in the present study. All
T2DM patients and healthy controls subjects were from
the First Affiliated Yijishan hospital with Wannan Medical
College. This protocol was approved by the Medical Ethics
Committee of the WanNan Medical College in China, and
all participants were provided written informed consent.
Blood pressure was measured on the right arm in a sitting
position after 15 min rest with a standard mercury sphyg-
momanometer. All participants had an overnight fast and
patients did not take their usual medication and insulin
before blood sampling.
Methods
Plasma creatinine (Cr), cystatin c (CYS-C), superoxide
dismutase (SOD), glucose, lipid levels and concentra-
tions of urinary albumin were determined with Hitachi
7600 biochemistry autoanalyzer (Hitachi, Tokyo, Japan).
All above reagents were purchased from BeiJing LEAD-
MAN BIOCHEMISTRY CO, LTD, China. HbA1c was
measured by HPLC using a Bio-Rad Variant II analyzer
(Bio-Rad Laboratories, Hercules, CA, USA). Plasma apoM
concentrations were assayed using a commercial ELISA
kit (Cloud-Clone Corp, Houston, TX, USA) according
to the manufacturer’s instructions. The concentrations
of apoM in the calibrator was determined using a standard
of known apoM concentration. All samples were diluted
1:5000 and analyzed in duplicate. The range of the stand-
ard curve was 0.312 ~ 20 ng/mL.
Amplifying DNA of apoM proximal promoter region
including SNPs C724del by RT-PCR and amplicons
sequencing
Detail sequence information of apoM and SNP ID number
are publicly available (http://www.ncbi.nlm.nih.gov/SNP).
According to the sequence, a pair of primers were de-
signed by primer premier 5.0 software (Premier Company,
Canada) as follows: forward primer: AGTCACTTGGT
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GCTATCC; reverse: primer: GTTGGTGTCAGGCAG
AAT, and the total sequence was 580 bp. The primers
were synthesized by Sangon Biotech Company (Shanghai,
China). Operation of extracting DNA from peripheral
blood sample of each subject should accord with the in-
structions from a commercial DNA extract Kit (TIANamp,
Beijing, China). Taq DNA polymerase, dNTPs, Polymerase
chain reaction (PCR) buffer, and MgCl2 were all in-
cluded in TIANamp Taq PCR Mastermix Kit purchased
from TIANamp (Beijing, China). PCR was performed
as follows: less than 0.1 ug genomic DNA template,
12.5 ul 2 × Taq PCR Mastermix, 10 umol of each pri-
mer and add ddH2O to a final reaction volume of 25 μl.
Thermal cycling was performed in Veriti® PCR Thermal
cycler (Applied Biosystems, America). The cycling pro-
gram consisted of 3 min of initial denaturation at 94 °C,
followed by 30 cycles at 95 °C for 30 s (temperature transi-
tion rate 3.9 °C/s), 60 °C for 30 s (temperature transition
rate 3.9 °C/s), and 72 °C for 30 s (temperature transition
rate 3.9 °C/s). PCR products of DNA including SNPs
rs805297 (C-1065A), rs9404941 (T-855C) and rs805296
(T-778C), C-724del were directly sequenced on an
automatic sequencer from Applied Biosystems (Model
3730, BGI, Shanghai, China).
Statistical analysis
Continuous variables were provided as mean ± SD and
categorical variables were expressed as percentages. Com-
parisons of the general characteristics between different
genotypes in two groups were statistically evaluated with
SPSS statistical package version 16.0 (Chicago, IL, USA).
Comparisons of the genotype distributions between the
two groups were tested by the linear-by-linear association
Chi-squared analyses. Allele frequencies, Hardy-Weinberg
equilibrium of genotype distributions, odds ratios (ORs)
and 95 % confidence intervals (CIs) were estimated by
the Chi-squared analyses. Analyses of linkage disequi-
librium (LD) between SNPs were determined by calcu-
lating pair-wise D’ and r2 statistics in unrelated individuals
using the SHEsis software online (http://analysis.bio-x.cn/
myAnalysis.php). Power calculations were performed by
SAS software (power and sample size, version 3.1). Signifi-
cance was established at a P value < 0.05.
Results
General characteristics of T2DM patients and healthy
controls
Comparisons of the baseline characteristics and plasma
parameters between T2DM patients (n = 259) and healthy
controls (n = 76) are shown in Table 1. There were no stat-
istical difference in age and sex between T2DM patients
and healthy controls (p = 0.940 and p = 0.450, respect-
ively). Lower HDL-C, apolipoproteinAI (apoA-I), apoM
(20.17 ± 10.03 ng/uL vs 24.48 ± 11.45 ng/uL, p = 0.004)
were seen in T2DM patients compared with those in
healthy control.
Allele frequencies and genotype distributions of apoM
promoter in T2DM patients and healthy controls
As showed in Table 2, C-1065A, T-855C, T-778C and C-
724del were found in the present study (Fig. 1). Geno-
type distributions of these four SNPs in T2DM patients
and healthy controls followed Hardy-Weinberg equilib-
rium (HWE, P > 0.05). C-1065A and T-855C showed no
statistically significant difference in allele frequencies
and genotype distributions between T2DM patients and
healthy controls. Besides that, this study did not find
the difference in allele frequencies and genotype distri-
butions of SNP T-778C in these two groups. In T2DM
patients, 212 patients (81.9 %) had the T/T genotype,
46 patients (17.8 %) had the T/C genotype and 1 pa-
tients (0.3 %) had the C/C genotype. While in healthy
control, the rate were 73.7 %, 26.3 %, 0 %, respectively.
The genotype distribution of SNP T-778C was not sta-
tistically different between T2DM patients and healthy
controls (P = 0.146). The minor C allele frequency of
SNP T-778C in the T2DM group was not significant
different with healthy controls (9.3 % vs 13.2 %, P =
0.162). In SNP C-724del, the frequency of del allele was







N (male/femal) 40/36 149/110 0.450
AGE (yrs) 56.24 ± 8.59 56.33 ± 11.49 0.940
SBP (mmHg) 117.36 ± 12.79 137.71 ± 20.89 0.000
DBP (mmHg) 76.00 ± 7.79 83.44 ± 11.40 0.000
Cr (umol/L) 64.80 ± 14.61 75.03 ± 31.73 0.000
CYS-C (mg/L) 0.97 ± 0.21 1.17 ± 0.50 0.000
SOD (U/mL) 106.70 ± 10.69 82.01 ± 25.78 0.000
FPG (mmol/L) 5.36 ± 0.36 9.45 ± 3.33 0.000
TC (mmol/L) 4.26 ± 0.52 4.46 ± 1.22 0.038
TG (mmol/L) 1.18 ± 0.42 2.19 ± 1.89 0.000
HDL-C (mmol/L) 1.41 ± 0.20 1.21 ± 0.32 0.000
LDL-C (mmol/L) 2.31 ± 0.41 2.53 ± 0.80 0.002
apoA-I (g/L) 1.66 ± 0.26 1.29 ± 0.34 0.000
apoB (g/L) 0.75 ± 0.18 0.90 ± 0.33 0.000
LP (a) (mg/L) 131.51 ± 113.31 157.07 ± 191.36 0.269
apoM (ng/uL) 24.48 ± 11.45 20.17 ± 10.03 0.004
Data mean ± SD
N number, M male, F female, SBP systolic blood pressure, DBP diastolic blood
pressure, Cr creatinine, CYS-C cystatin c, SOD superoxide dismutase, FBG fasting
blood glucose, TG triglycerides, TC total cholesterol, LDL-C low-density lipoprotein
cholesterol, HDL-C high-density lipoprotein cholesterol, apo apolipoprotein,
LP (a) Lipoprotein (a)
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6.4 % in T2DM patients and only 2.0 % in healthy con-
trols (P = 0.035). In T2DM patients, 228 patients
(88.0 %) had the C/C genotype, 29 patients (11.2 %)
had the C /del genotype and 2 patients (0.8 %) had the
del/del genotype. While in healthy controls, rates were
96.1 %, 3.9 %, 0 %, respectively. The genotype distribution
was also significantly different between T2DM patients
and healthy controls (P = 0.040).
Correlation between clinical characteristics and SNPs
rs805297 (C-1065A), rs9404941 (T-855C), rs805296
(T-778C), C-724del in T2DM patients and healthy controls
Clinical characteristics and lipid levels of T2DM patients
and healthy controls in relation to the genotypes of SNPs
rs805297 (C-1065A), rs9404941 (T-855C), rs805296
(T-778C) and C-724del were showed in Tables 3, 4, 5, 6
respectively. In SNP C-724del, the mean TC level was
Table 2 Allele frequencies and genotype distributions of apoM proximal promoter region in healthy control and T2DM patients





OR (95 % CI) P-
value
Healthy control (%frequencies) T2DM (%frequencies) P-value of HWE P-
value11 12 22 11 12 22 Control T2DM
C-1065A C 67.1 67.8 1.030 0.879 36 30 10 115 121 23 0.356 0.265 0.878
rs805297 A 32.9 32.2 0.701 ~ 1.515 (47.4) (39.5) (13.1) (44.4) (46.7) (8.9)
T-855C T 77.0 78.0 1.033 0.791 47 23 6 162 80 17 0.202 0.107 0.801
rs9404941 C 23.0 22.0 0.672 ~ 1.588 (61.8) (30.3) (7.9) (62.5) (30.9) (6.6)
T-778C T 86.8 90.7 1.484 0.162 56 20 0 212 46 1 0.187 0.366 0.146
rs805296 C 13.2 9.3 0.851 ~ 2.587 (73.7) (26.3) (0) (81.9) (17.8) (0.3)
C-724del C 98.0 93.6 3.379 0.035 73 3 0 228 29 2 0.861 0.323 0.040
Del 2.0 6.4 1.022 ~ 11.176 (96.1) (3.9) (0.00) (88.0) (11.2) (0.8)
P-Value <0.05 was shown in bold
Fig. 1 Four polymorphic sites, rs805297 (C-1065A), rs9404941 (T-855C), rs805296 (T-778C) and C-724del were confirmed in apoM promoter gene.
a-b was a compound heterozygote for C-1065A. a-a, a-c were the sequence data of homozygotes for -1065C, -1065A, respectively. Similarly,
b-b, c-b, d-b represent the compound heterozygote for T-855C, T-778C, C-724del, respectively. b-a, c-a, d-a were the sequence data of homozygotes
for -855T, -778T, -724C, respectively. b-c, c-c, d-c were the sequence data of homozygotes for -855C, -778C, -724del, respectively. The arrow presented
the mutation site
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Table 3 C-724del. Genotype and clinical characteristics of T2DM patients and healthy control
Healthy control T2DM P-value
CC C/- + −/− CC C/- + −/− CC vs. (C/- + −/−)
in healthy control
CC vs. (C/- + −/−)
in T2DM patients
N (male/femal) 40/33 0/3 131/87 18/13 0.203 0.949
AGE (yrs) 52.67 ± 4.93 56.54 ± 7.68 56.26 ± 11.24 56.81 ± 13.14 0.392 0.830
SBP (mmHg) 110.00 ± 10.00 117.81 ± 13.15 137.93 ± 20.45 136.06 ± 24.20 0.314 0.641
DBP (mmHg) 74.00 ± 4.00 76.00 ± 8.07 83.64 ± 11.40 81.97 ± 11.44 0.672 0.444
DM duration (yrs) 6.55 ± 5.87 6.41 ± 5.61 0.895
HbA1c (%) 9.56 ± 2.50 9.58 ± 2.37 0.960
Cr (umol/L) 50.50 ± 9.03 65.01 ± 14.63 75.13 ± 32.65 74.30 ± 24.27 0.094 0.891
CYS-C (mg/L) 0.86 ± 0.10 0.98 ± 0.22 1.18 ± 0.51 1.15 ± .38 0.362 0.798
SOD (U/mL) 107.67 ± 15.50 106.87 ± 10.29 82.63 ± 25.96 77.42 ± 24.34 0.898 0.292
FPG (mmol/L) 5.19 ± 0.33 5.37 ± 0.37 9.43 ± 3.35 9.59 ± 3.22 0.409 0.807
TC (mmol/L) 4.20 ± 0.16 4.28 ± 0.52 4.52 ± 1.25 4.05 ± .93 0.779 0.046
TG (mmol/L) 0.64 ± 0.11 1.20 ± 0.41 2.22 ± 1.95 1.98 ± 1.35 0.022 0.503
HDL-C (mmol/L) 1.49 ± 0.11 1.42 ± 0.19 1.22 ± 0.31 1.19 ± 0.37 0.560 0.706
LDL-C (mmol/L) 2.42 ± 0.07 2.31 ± 0.41 2.55 ± 0.80 2.32 ± 0.74 0.125 0.119
ApoA-I (g/L) 1.63 ± 0.11 1.68 ± 0.26 1.30 ± 0.34 1.22 ± 0.32 0.748 0.210
ApoB (g/L) 0.71 ± 0.09 0.75 ± 0.18 0.91 ± 0.34 0.83 ± 0.29 0.706 0.228
LP (a) (mg/L) 210.37 ± 54.13 129.60 ± 115.45 157.20 ± 199.35 156.10 ± 119.13 0.234 0.976
apoM (ng/uL) 23.63 ± 8.80 24.93 ± 11.78 20.44 ± 10.21 18.20 ± 8.53 0.851 0.245
Data are means ± SD. P-Value <0.05 was shown in bold
Table 4 C1065A. Genotype and clinical characteristics of T2DM patients and healthy control
Healthy control T2DM P-value
CC CA + AA CC CA + AA CC vs. (CA + AA)
in healthy control
CC vs. (CA + AA)
in T2DM patients
N (male/femal) 18/18 22/18 66/49 83/61 0.663 0.968
AGE (yrs) 55.00 ± 8.24 57.35 ± 8.84 57.50 ± 10.41 55.39 ± 12.23 0.236 0.141
SBP (mmHg) 118.31 ± 13.08 116.50 ± 12.62 139.84 ± 22.64 136.01 ± 19.29 0.542 0.142
DBP (mmHg) 76.39 ± 8.38 75.65 ± 7.32 85.13 ± 11.59 82.09 ± 11.10 0.683 0.033
DM duration (yrs) 6.32 ± 5.62 6.71 ± 6.00 0.600
HbA1c (%) 9.80 ± 2.51 9.37 ± 2.45 0.171
Cr (umol/L) 66.38 ± 16.05 63.39 ± 13.22 72.97 ± 30.90 76.68 ± 32.38 0.376 0.351
CYS-C (mg/L) 0.97 ± 0.20 0.97 ± 0.22 1.19 ± 0.53 1.16 ± 0.46 0.892 0.581
SOD (U/mL) 107.25 ± 10.84 106.20 ± 10.67 81.30 ± 19.61 82.58 ± 29.86 0.672 0.692
FPG (mmol/L) 5.28 ± 0.38 5.42 ± 0.33 9.92 ± 3.55 9.07 ± 3.10 0.087 0.041
TC (mmol/L) 4.18 ± 0.51 4.33 ± 0.53 4.49 ± 1.44 4.44 ± 1.02 0.206 0.767
TG (mmol/L) 1.16 ± 0.42 1.20 ± 0.42 2.19 ± 1.63 2.20 ± 2.08 0.647 0.957
HDL-C (mmol/L) 1.42 ± 0.20 1.41 ± 0.20 1.20 ± 0.31 1.22 ± 0.32 0.875 0.552
LDL-C (mmol/L) 2.24 ± 0.40 2.38 ± 0.41 2.53 ± 0.82 2.52 ± 0.78 0.142 0.936
ApoA-I (g/L) 1.64 ± 0.25 1.68 ± 0.28 1.27 ± 0.36 1.32 ± 0.31 0.500 0.240
ApoB (g/L) 0.72 ± 0.17 0.77 ± 0.19 0.89 ± 0.32 0.91 ± 0.35 0.232 0.597
LP (a) (mg/L) 117.72 ± 86.94 143.92 ± 132.57 156.66 ± 231.64 157.40 ± 152.60 0.317 0.975
apoM (ng/uL) 24.34 ± 11.02 24.62 ± 11.96 19.21 ± 8.46 20.93 ± 11.10 0.917 0.171
Data are means ± SD. P-Value <0.05 was shown in bold
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Table 5 T855C. Genotype and clinical characteristics of T2DM patients and healthy control
Healthy control T2DM P-value
TT TC + CC TT TC + CC TT vs. (TC + CC) in
healthy control
TT vs. (TC + CC)
in T2DM patients
N (male/femal) 21/26 19/10 90/72 59/38 0.077 0.406
AGE (yrs) 56.83 ± 9.37 55.28 ± 7.19 56.12 ± 12.14 56.68 ± 10.35 0.447 0.703
SBP (mmHg) 116.28 ± 13.45 119.10 ± 11.64 138.06 ± 20.66 137.13 ± 21.37 0.353 0.732
DBP (mmHg) 75.02 ± 7.37 77.59 ± 8.31 83.54 ± 11.54 83.27 ± 11.22 0.165 0.851
DM duration (yrs) 6.41 ± 5.84 6.74 ± 5.84 0.657
HbA1c (%) 9.61 ± 2.51 9.48 ± 2.44 0.663
Cr (umol/L) 62.20 ± 13.06 69.02 ± 16.17 74.91 ± 33.70 75.23 ± 28.29 0.047 0.938
CYS-C (mg/L) 0.95 ± 0.21 0.99 ± 0.21 1.18 ± 0.50 1.16 ± 0.48 0.418 0.789
SOD (U/mL) 106.64 ± 11.45 106.79 ± 9.53 83.19 ± 29.26 80.03 ± 18.55 0.952 0.341
FPG (mmol/L) 5.35 ± 0.36 5.36 ± 0.36 9.42 ± 3.29 9.50 ± 3.41 0.931 0.858
TC (mmol/L) 4.35 ± 0.48 4.12 ± 0.57 4.55 ± 1.36 4.32 ± .94 0.075 0.149
TG (mmol/L) 1.18 ± 0.39 1.18 ± 0.47 2.27 ± 2.03 2.07 ± 1.63 0.956 0.409
HDL-C (mmol/L) 1.42 ± 0.19 1.41 ± 0.22 1.21 ± 0.32 1.22 ± 0.31 0.940 0.810
LDL-C (mmol/L) 2.40 ± 0.37 2.18 ± 0.43 2.56 ± 0.83 2.47 ± 0.74 0.023 0.370
ApoA-I (g/L) 1.67 ± 0.26 1.64 ± 0.28 1.30 ± 0.34 1.28 ± 0.34 0.640 0.713
ApoB (g/L) 0.76 ± 0.18 0.72 ± 0.19 0.94 ± 0.37 0.85 ± 0.27 0.334 0.034
LP (a) (mg/L) 154.47 ± 128.70 94.30 ± 69.74 161.87 ± 219.55 149.06 ± 132.16 0.023 0.603
apoM (ng/uL) 26.63 ± 11.92 21.02 ± 9.87 20.55 ± 10.55 19.53 ± 9.13 0.037 0.427
Data are means ± SD. P-Value <0.05 was shown in bold
Table 6 T778C. Genotype and clinical characteristics of T2DM patients and healthy control
Healthy control T2DM P-value
TT TC + CC TT TC + CC TT vs. (TC + CC)
in healthy control
TT vs. (TC + CC)
in T2DM patients
N (male/femal) 29/27 11/9 131/97 18/13 0.805 0.949
AGE (yrs) 55.21 ± 8.76 59.10 ± 7.57 56.12 ± 11.71 56.81 ± 13.34 0.082 0.764
SBP (mmHg) 118.73 ± 12.32 113.50 ± 13.58 136.83 ± 20.59 136.06 ± 24.20 0.117 0.851
DBP (mmHg) 76.57 ± 8.23 74.40 ± 6.34 83.11 ± 11.20 81.97 ± 11.44 0.288 0.598
DM duration (yrs) 6.49 ± 5.81 6.41 ± 5.61 0.943
HbA1c (%) 9.51 ± 2.48 9.58 ± 2.37 0.875
Cr (umol/L) 64.42 ± 13.46 65.88 ± 17.78 76.19 ± 33.37 74.30 ± 24.27 0.705 0.761
CYS-C (mg/L) 0.96 ± 0.19 0.98 ± 0.27 1.19 ± 0.53 1.15 ± .38 0.738 0.730
SOD (U/mL) 106.93 ± 10.18 106.05 ± 12.28 80.89 ± 20.97 77.42 ± 24.34 0.755 0.401
FPG (mmol/L) 5.38 ± 0.37 5.28 ± 0.32 9.43 ± 3.38 9.59 ± 3.22 0.249 0.813
TC (mmol/L) 4.24 ± 0.55 4.33 ± 0.45 4.36 ± 0.95 4.05 ± .93 0.525 0.097
TG (mmol/L) 1.16 ± 0.41 1.25 ± 0.45 2.14 ± 1.60 1.98 ± 1.35 0.401 0.596
HDL-C (mmol/L) 1.42 ± 0.20 1.40 ± 0.18 1.20 ± 0.31 1.19 ± 0.37 0.806 0.840
LDL-C (mmol/L) 2.30 ± 0.41 2.35 ± 0.41 2.49 ± 0.76 2.32 ± 0.74 0.596 0.224
ApoA-I (g/L) 1.65 ± 0.24 1.69 ± 0.34 1.28 ± 0.32 1.22 ± 0.32 0.625 0.350
ApoB (g/L) 0.75 ± 0.18 0.75 ± 0.18 0.89 ± 0.31 0.83 ± 0.29 0.950 0.318
LP (a) (mg/L) 121.14 ± 97.43 160.56 ± 148.32 160.62 ± 203.15 156.10 ± 119.13 0.183 0.904
apoM (ng/uL) 23.35 ± 10.91 27.68 ± 12.58 20.05 ± 10.21 18.20 ± 8.53 0.148 0.337
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lower in T2DM patients with mutant allele compared to
the wide-type homozygotes carriers (P = 0.046).
Haplotype analyses
We estimated all possible haplotypes from the observed
genotypes of rs805297 (C-1065A), rs9404941 (T-855C),
rs805296 (T-778C) and C-724del by SHEsis software
online (http://analysis.bio-x.cn/myAnalysis.php). The link-
age disequilibrium analysis showed no obvious LD between
any of two SNPs (Table 7). Haplotype (frequency > 3 %)
derived from the four SNPs of apoM between T2DM
and controlss was showed in Table 8. Among these four
haplotypes, the haplotype T-T-del (-855-778-724), C-T-
del (-1065-778-724) and C-T-del (-1065-855-724) were
found to be associated with an increased risk of T2DM
(OR = 3.268 95 % CI = 0.977 ~ 10.928; P = 0.040, OR =
3.375 95 % CI = 1.021 ~ 11.163; P = 0.035 and OR =
3.309 95 % CI = 0.998 ~ 10.978, P = 0.039, respectively).
The power calculation showed that the study had 78.9 %
power to detect differences of C-724del between T2DM
and controls subjects at a significance level of 0.05.
Discussion
In the present study, we performed genetic association
analysis on apoM promoter SNPs rs805297 (C-1065A),
rs9404941 (T-855C), rs805296 (T-778C) and C-724del
in 259 T2DM patients and 76 healthy controls from
an eastern Han Chinese population. It clearly demonstrated
that C-724del polymorphism in the promoter region ap-
peared to increase susceptibility to T2DM. However, the
results of this study did not support an association between
rs805296 (T-778C) polymorphism and T2DM susceptibility
in eastern Han Chinese. Besides that, SNPs rs805297
(C-1065A) and rs9404941 (T-855C) had no significant
difference in allele frequencies and genotype distribu-
tions between T2DM patients and healthy controls. Lower
plasma apoM levels were also seen in T2DM patients than
healthy controls in our study just as previous research
[17]. However, the plasma apoM levels were not statis-
tically different in T2DM patients with rs805297 (C-
1065A), rs9404941 (T-855C), rs805296 (T-778C) and
C-724del mutant allele compared to the wide-type ho-
mozygotes carriers respectively. Consistently, the haplotype
analysis showed that the haplotype T-T-del (-855-778-724),
C-T-del (-1065-778-724) and C-T-del (-1065-855-724) were
associated with an increased risk for T2DM.
ApoM was a plasma apolipoprotein which was particu-
larly present in HDL-C and to a lesser extent in TG-rich
lipoproteins (TGRLP) and LDL-C [1]. It was required
for prebeta-HDL-C formation and cholesterol efflux to
HDL-C [7, 18, 19]. Besides that, apoM was associated
with apoA-I, which was the main apolipoprotein in HDL
and might be an independent predictor of apoA-I catabol-
ism in overweight-obese, insulin resistant men [20, 21].
There were many evidences to suggest the involvement of
apoM in the development of T2DM. Xu, et al. found that
the apoM expression was reduced in alloxan-diabetic mice
models [22], while Nojiri, et al. recently discovered the
opposite result in streptozotocin-induced diabetic mice
models [23]. Similarly, plasma apoM levels were lower
in T2DM patients [17], our study also confirmed this
result, so apoM might be a useful serum marker for the
identification of T2DM, but the exact reasons were still
unknown. ApoM was particularly present in HDL-C
particles [4] and its expression was associated with liver
X receptor (LXR) [24], fork head box A2 (Foxa2) [25, 26],
liver receptor homolog-1 (LRH-1) [27] hepatic nuclear
factor-1α (HNF-1α) [28], peroxisome proliferator-activated
receptor beta/delta/gamma [29, 30], protein kinase C
(PKC) [31], leptin and insulin [23, 32] et al., all of
which were related to glucose metabolism. Animals
and cell culture suggested that hyperglycemia could down-
regulate apoM expression [33]. Moreover, apoM over ex-
pression might have a potential role in improving insulin
resistance [34], further explain that modulating apoM ex-
pression might against insulin resistance in type 2 diabetes.
Plasma levels of apoM were also decreased in maturity-
onset diabetes of the young (MODY3) subjects, might
attribute to the hepatocyte nuclear factor-1α (HNF-1α)-
dependent impairment of apoM expression leaded by
heterozygous HNF-1α mutations [35, 36].
This study found that the frequency of del allele in
SNP C-724del were significantly increased in T2DM pa-
tients compared with healthy controls. In Zhou’ research,
Table 7 Linkage disequilibrium tests
Haplotype rs9404941 rs805296 C-724del
D’ r2 D’ r2 D’ r2
rs805297 0.892 0.109 0.749 0.030 0.995 0.027
rs9404941 - - 0.998 0.032 0.785 0.010
rs805296 - - - - 0.940 0.006
Table 8 Association of apoM promoter haplotypes with T2DM
Haplotype Haplotype frequency OR (95 % CI) P-
valueCases Controls
H1 -855-778-724
T T del 0.061 0.019 3.268 (0.977 ~ 10.928) 0.040
H2 -1065-778-724
C T del 0.064 0.020 3.375 (1.021 ~ 11.163) 0.035
H3 -1065-855-724
C T del 0.062 0.020 3.309 (0.998 ~ 10.978) 0.039
Haplotype with frequency less than 3 % was pooled and not analyzed.
P-Value <0.05 is shown in bold
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they reported that 290 individuals (88.0 %) had the C/C
genotype, 18 individuals (5.8 %) had the C/del geno-
type, 1 individuals (0.3 %) had the del/del genotype and
the frequency of del allele was 3.2 % in total 309 east-
ern Han Chinese controls [14]. The frequency of del
allele were also significantly different between T2DM
patients and above healthy controls (P = 0.013), both
together, demonstrated that SNP C-724del was signifi-
cantly associated with a higher risk for T2DM. In gen-
etics, SNPs in the promoter region could affect the
gene transcription and even protein expression. Zheng
et al. found that constructs C-724del in apoM promoter
region showed significant decreased promoter activity
[14, 15]. That the expression of apoM was lower while
the frequency of C-724del mutant allele in T2DM pa-
tients was higher compared with those healthy controls,
suggested that this polymorphisms, in promoter region,
might contribute to the down-regulation of apoM expres-
sion. Unfortunately, the lowing of plasma apoM levels of
-C724del mutant allele carriers compared to the wide-type
homozygotes carriers in T2DM patients was not statisti-
cally different (18.20 ± 8.53 ng/uL vs 20.44 ± 10.21 ng/uL,
P = 0.245) in present study, so further researchs were
needed by enlarging the sample.
ApoM SNP rs805396 (T-778C) was strongly associated
with T1DM in both Han and Swedish populations, dem-
onstrated that allele C of apoM SNP rs805396 (T-778C)
may increase promoter activity and confer the risk sus-
ceptibility to the development of T1DM [9]. Moreover,
apoM SNP rs805396 (T-778C) was also strongly associ-
ated with T2DM in Han [10], showed that apoM SNP
rs805396 (T-778C) might be involved in the common
pathogenesis of both T1DM and T2DM. It would have
been ideal if the previous found that the SNP rs805296
(T-778C) were associated with T2DM in northern China
were reproduced in this eastern Han Chinese. Unfortu-
nately, the allele frequencies and genotype distributions
between T2DM patients and healthy controls were not
statistically different in this study just as previous re-
search in Hong Kong Chinese population [11], the pos-
sible reason might be the difference in genotype of SNPs
in different area of china [12, 13]. In addition, SNPs
rs805297 (C-1065A) and rs9404941 (T-855C) had no sig-
nificant difference in allele frequencies and genotype dis-
tributions between T2DM patients and healthy controls
just as previous report [10]. It should be mentioned that
the result of the present study needs further replications
in other areas and races to avoid spurious associations
which are common in genetic association researchs.
Conclusions
In conclusion, the polymorphism C-724del in the pro-
moter region of the apoM gene could confer the risk of
T2DM among eastern Han Chinese. Unfortunately, the
lowing of plasma apoM levels of C-724del mutant allele
carriers compared to the wide-type homozygotes carriers
in T2DM patients was not statistically different in present
study, so further researchs were needed by enlarging the
sample.
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